Oct. 24, 2025: State Advocacy Update

| 1 Min Read
Contents
  1. New issue brief provides kratom and tianeptine basics, AMA recommendations
  2. More articles in this issue

New issue brief provides kratom and tianeptine basics, AMA recommendations

A new issue brief (PDF) from the AMA Advocacy Resource Center provides key information about kratom and tianeptine—two unregulated substances that have generated increasing reports of public health harms. The issue brief includes basic information about the substances, including the fact that neither has been approved by the U.S. Food and Drug Administration.

Haven't subscribed?

Stay current on the latest on the issues impacting physicians, patients and the healthcare environment with the AMA’s Advocacy Update newsletter.

Sign Up/Create Account

The AMA recommends the safety and efficacy of kratom should be determined through research and clinical trials and subsequently evaluated by the relevant regulatory entities for its appropriateness for sale and potential oversight via the Controlled Substances Act, before it can be marketed, purchased or prescribed. The AMA also advocates to ban the sale of tianeptine directly to the public in the absence of research into the safety and efficacy of the substance. 

Your Powerful Ally

Through AMA advocacy and policymaking, we are addressing the issues important to you—together—and shaping what’s next for physicians.

Join Us

FEATURED STORIES

Doctor places reassuring hands on a smiling patient

Why bipartisan agreement on Medicare payment reform means so much

| 5 Min Read
New Mexico State Capitol

New Mexico opens door for doctors with tort reforms, other fixes

| 7 Min Read
Office chair in a human palm

Why physician well-being leaders need a seat at the table

| 6 Min Read
Features of a human face covered in certain areas

AMA backs bill aimed at combating AI-generated deepfakes

| 4 Min Read